ONTAK

DRUG10 trials

Conditions

CHRONIC LYMPHOCYTIC B-LEUKEMIAEpithelial Ovarian CancerExtraovarian Peritoneal CancerFallopian Tube CarcinomaLeukemia, Lymphocytic, ChronicLymphoma, B-cellLymphoma, Low-gradeLymphoma, T-Cell, Cutaneous

Phase 1

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells

WithdrawnNCT00224354

Baylor College of MedicineCHRONIC LYMPHOCYTIC B-LEUKEMIA

Start: 2005-09-30End: 2009-12-31Updated: 2012-05-21

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

CompletedNCT00425672

University of WashingtonMale Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer +3

Start: 2005-09-30Updated: 2018-12-05

Phase 2

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

CompletedNCT00051025

Eisai Inc.Lymphoma, B-cell, Lymphoma, Low-grade, Non-Hodgkin's Lymphoma

Start: 2000-05-31End: 2006-09-30Updated: 2012-07-13

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

CompletedNCT00055146

Eisai Inc.Leukemia, Lymphocytic, Chronic

Start: 2003-03-31End: 2006-05-31Target: 41Updated: 2009-04-17

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

CompletedNCT00337987

Yale UniversityPeripheral T-Cell Lymphoma

Start: 2005-11-30End: 2008-01-31Updated: 2015-02-27

Vaccination Plus Ontak in Patients With Metastatic Melanoma

TerminatedNCT00515528

University of ChicagoMelanoma

Start: 2007-04-23End: 2016-03-31Updated: 2021-01-26

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

TerminatedNCT00726037

Loyola UniversityMetastatic Pancreatic Cancer

Start: 2008-10-31End: 2012-01-31Updated: 2016-09-29

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

CompletedNCT00880360

The University of Texas Health Science Center at San AntonioEpithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma

Start: 2007-02-28End: 2010-04-30Updated: 2018-03-27

Phase 4

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

CompletedNCT00051012

Eisai Inc.Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome

Start: 1995-09-30End: 2006-12-31Target: 86Updated: 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

CompletedNCT00050999

Eisai Inc.Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome

Start: 1995-06-30End: 2006-12-31Target: 195Updated: 2008-03-05

Related Papers

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Journal for ImmunoTherapy of Cancer2016-06-0229 citations

Effect of denileukin diftitox (DD) on vaccine-induced T-cell responses and depletion of Tregs in melanoma.